{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:21:02Z","timestamp":1780050062783,"version":"3.53.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"DOI":"10.1097\/mph.0b013e31827e91bc","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T09:42:25Z","timestamp":1360748545000},"source":"Crossref","is-referenced-by-count":8,"title":["Hepatotoxicity From Arsenic Trioxide for Pediatric Acute Promyelocytic Leukemia"],"prefix":"10.1097","volume":"Publish Ahead of Print","author":[{"given":"Liangchun","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20210227","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable.","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"R2-24-20210227","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia.","volume":"114","author":"Tallman","year":"2009","journal-title":"Blood"},{"key":"R3-24-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.moh.0000148552.93303.45","article-title":"Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.","volume":"12","author":"Chou","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"R4-24-20210227","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.0813280106","article-title":"Long-term efficacy and safety of all-trans retinoic acidarsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.","volume":"106","author":"Hu","year":"2009","journal-title":"PNAS"},{"key":"R5-24-20210227","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.leu.2403480","article-title":"Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.","volume":"18","author":"George","year":"2004","journal-title":"Leukemia"},{"key":"R7-24-20210227","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.bbmt.2009.07.010","article-title":"Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.","volume":"15","author":"Thirugnanam","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-24-20210227","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00024669-200605030-00005","article-title":"Arsenic trioxide, its use in the treatment of acute promyelocytic leukemia.","volume":"5","author":"Sanz","year":"2006","journal-title":"Am J Cancer"},{"key":"R9-24-20210227","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/cncr.11314","article-title":"Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. anderson experience.","volume":"97","author":"Lazo","year":"2003","journal-title":"Cancer"},{"key":"R10-24-20210227","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/sj.leu.2404165","article-title":"Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity.","volume":"20","author":"Mathews","year":"2006","journal-title":"Leukemia"},{"key":"R11-24-20210227","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood-2009-07-230805","article-title":"Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.","volume":"115","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"R12-24-20210227","first-page":"1231","article-title":"Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence.","volume":"90","author":"Sanz","year":"2005","journal-title":"Haematologica"},{"key":"R13-24-20210227","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.","volume":"107","author":"Mathews","year":"2006","journal-title":"Blood"},{"key":"R14-24-20210227","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.leukres.2011.06.002","article-title":"The efficacy and safety of arsenic trioxide with or without all-transretinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk Res"},{"key":"R15-24-20210227","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/mdj019","article-title":"Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA andor chemotherapy.","volume":"17","author":"Ghavamzadeh","year":"2006","journal-title":"Ann Oncol"},{"key":"R16-24-20210227","first-page":"1S","article-title":"Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710.","volume":"25","author":"Powell","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R17-24-20210227","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.critrevonc.2004.08.009","article-title":"Treatment concepts of acute promyelocytic leukemia.","volume":"56","author":"Lengfelder","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"R18-24-20210227","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ajh.10138","article-title":"Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.","volume":"70","author":"Mathews","year":"2002","journal-title":"Am J Hematol"},{"key":"R19-24-20210227","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1200\/JCO.2011.35.1031","article-title":"Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.","volume":"29","author":"Estey","year":"2011","journal-title":"J Clin Oncol"},{"key":"R20-24-20210227","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2010.32.2107","article-title":"Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.","volume":"29","author":"Ghavamzadeh","year":"2011","journal-title":"J Clinic Oncol"},{"key":"R21-24-20210227","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2011.38.7654","article-title":"Use of arsenic trioxide as a first-line single agent in the treatment of acute promyelocytic leukemia.","volume":"30","author":"Keyhani","year":"2012","journal-title":"J Clinic Oncol"},{"key":"R22-24-20210227","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.","volume":"28","author":"Mathews","year":"2010","journal-title":"J Clinic Oncol"},{"key":"R23-24-20210227","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.","volume":"19","author":"Soignet","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-900000000-99163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T14:08:34Z","timestamp":1647439714000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-900000000-99163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e31827e91bc","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,1]]}}}